CN105209481B - 自组装合成蛋白 - Google Patents

自组装合成蛋白 Download PDF

Info

Publication number
CN105209481B
CN105209481B CN201480026671.3A CN201480026671A CN105209481B CN 105209481 B CN105209481 B CN 105209481B CN 201480026671 A CN201480026671 A CN 201480026671A CN 105209481 B CN105209481 B CN 105209481B
Authority
CN
China
Prior art keywords
protein
recombinant synthetic
subunit
recombinant
synthetic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026671.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209481A (zh
Inventor
基思·艾伦·查尔顿
埃里克·东特
丹尼尔·T·韦哈马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insrebaio Ltd
In3bio Ltd
Original Assignee
Insrebaio Ltd
Bioven 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insrebaio Ltd, Bioven 3 Ltd filed Critical Insrebaio Ltd
Priority to CN202010734323.9A priority Critical patent/CN111978409B/zh
Publication of CN105209481A publication Critical patent/CN105209481A/zh
Application granted granted Critical
Publication of CN105209481B publication Critical patent/CN105209481B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480026671.3A 2013-03-15 2014-03-17 自组装合成蛋白 Active CN105209481B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010734323.9A CN111978409B (zh) 2013-03-15 2014-03-17 自组装合成蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791268P 2013-03-15 2013-03-15
US61/791,268 2013-03-15
PCT/IB2014/001125 WO2014140894A2 (en) 2013-03-15 2014-03-17 Self-assembling synthetic proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010734323.9A Division CN111978409B (zh) 2013-03-15 2014-03-17 自组装合成蛋白

Publications (2)

Publication Number Publication Date
CN105209481A CN105209481A (zh) 2015-12-30
CN105209481B true CN105209481B (zh) 2020-08-25

Family

ID=51225849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026671.3A Active CN105209481B (zh) 2013-03-15 2014-03-17 自组装合成蛋白
CN202010734323.9A Active CN111978409B (zh) 2013-03-15 2014-03-17 自组装合成蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010734323.9A Active CN111978409B (zh) 2013-03-15 2014-03-17 自组装合成蛋白

Country Status (14)

Country Link
US (3) US10736948B2 (enExample)
EP (1) EP2970409A2 (enExample)
JP (1) JP6873530B2 (enExample)
KR (2) KR102391734B1 (enExample)
CN (2) CN105209481B (enExample)
AU (1) AU2014229561B2 (enExample)
BR (1) BR112015023402A2 (enExample)
CA (1) CA2904506A1 (enExample)
HK (1) HK1214606A1 (enExample)
IL (3) IL286537B (enExample)
MX (2) MX385451B (enExample)
MY (1) MY187936A (enExample)
RU (1) RU2747857C2 (enExample)
WO (1) WO2014140894A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
CA3070034A1 (en) * 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
CN120904351A (zh) * 2019-06-25 2025-11-07 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
CN114019166B (zh) * 2021-09-27 2024-02-27 浙江省食品药品检验研究院 一种检测龙葵素的试纸条及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5894018A (en) * 1993-12-09 1999-04-13 Centro De Immunologia Molecular Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivative thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CN1905892A (zh) * 2003-12-05 2007-01-31 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
WO2012116453A1 (en) * 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001027144A2 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
DE60232603D1 (de) 2001-06-21 2009-07-23 Teijin Ltd Nahinfrarot-schutzfolie
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
EP1490481A4 (en) 2001-12-14 2005-12-07 Centocor Inc CLONAL CELL LINES OF MYELOMES FOR PRODUCING PROTEINS IN A CHEMICALLY DEFINED ENVIRONMENT
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
US7946815B2 (en) 2007-03-27 2011-05-24 Siemens Energy, Inc. Airfoil for a gas turbine engine
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
CN101945666A (zh) 2007-12-19 2011-01-12 Mivac发展股份公司 治疗自身免疫和过敏性疾病的组合物及方法
EP2288380B1 (en) 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
JP2010050586A (ja) 2008-08-20 2010-03-04 Nec Corp 通信装置及びそれに用いる装置コンポーネント複合冗長化方法
US20120088819A1 (en) * 2008-10-31 2012-04-12 Makoto Inoue Method for enhancing expression of recombinant protein
JP5734201B2 (ja) * 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
JP2011097930A (ja) * 2009-10-07 2011-05-19 Hokkaido Univ 光活性化生理機能センサータンパク質
RU2480524C2 (ru) * 2010-09-13 2013-04-27 Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН Конструкция на основе белковой пары барназа-барстар и способ ее получения
CN102604993B (zh) 2012-01-10 2013-03-20 天津耀宇生物技术有限公司 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5894018A (en) * 1993-12-09 1999-04-13 Centro De Immunologia Molecular Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivative thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CN1905892A (zh) * 2003-12-05 2007-01-31 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
WO2012116453A1 (en) * 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chain D, Cholera Toxin B-Pentamer Complexed With Gm1 Pentasaccharide;Merritt,E.A等;《GeneBank》;20121010;第3页ORIGIN部分 *
Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response;Shenghua Li等;《Molecular Immunology》;20090309;摘要，第1720页图1（b） *
Shenghua Li等.Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response.《Molecular Immunology》.2009, *

Also Published As

Publication number Publication date
WO2014140894A2 (en) 2014-09-18
CN111978409B (zh) 2024-01-26
RU2015143217A (ru) 2017-04-27
AU2014229561A1 (en) 2015-10-29
IL273051A (en) 2020-04-30
KR20150139513A (ko) 2015-12-11
MX385451B (es) 2025-03-18
HK1214606A1 (zh) 2016-07-29
US12433939B2 (en) 2025-10-07
IL273051B (en) 2021-10-31
JP6873530B2 (ja) 2021-05-19
US11419923B2 (en) 2022-08-23
IL286537A (en) 2021-10-31
BR112015023402A2 (pt) 2017-08-22
CN105209481A (zh) 2015-12-30
IL286537B (en) 2022-07-01
US20200297827A1 (en) 2020-09-24
CN111978409A (zh) 2020-11-24
IL241116B (en) 2020-03-31
KR102391734B1 (ko) 2022-04-29
AU2014229561B2 (en) 2018-06-07
RU2019109120A (ru) 2019-06-13
MX2021010021A (es) 2021-12-10
MY187936A (en) 2021-10-29
IL241116A0 (en) 2015-11-30
JP2016517402A (ja) 2016-06-16
KR102427429B1 (ko) 2022-08-01
US10736948B2 (en) 2020-08-11
US20160095910A1 (en) 2016-04-07
MX2015012461A (es) 2016-08-08
WO2014140894A3 (en) 2015-02-19
CA2904506A1 (en) 2014-09-18
US20230042534A1 (en) 2023-02-09
KR20210005294A (ko) 2021-01-13
RU2747857C2 (ru) 2021-05-17
EP2970409A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US12433939B2 (en) Self-assembling synthetic proteins comprising cholera toxin beta subunit
US12030920B2 (en) Recombinant proteins and their therapeutic uses
HK40041859A (en) Self-assembling synthetic proteins
RU2801230C9 (ru) Самособирающиеся синтетические белки
RU2801230C2 (ru) Самособирающиеся синтетические белки
CN114269792B (zh) 稳定的嵌合合成蛋白及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Great Britain

Applicant after: INSREBAIO LIMITED

Applicant after: Keith Allen Charlton

Applicant after: Eric East

Applicant after: Daniel T. Weihamar

Address before: Great Britain

Applicant before: Bai Aowensirui company limited

Applicant before: Keith Allen Charlton

Applicant before: Eric East

Applicant before: Daniel T. Weihamar

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant